Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High levels of traumatic stress found in caregivers of adult cancer patients

2.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

3.

Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Scientists develop scans that light up aggressive cancer tumors for better treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot